<bill session="116" type="s" number="4867" updated="2023-01-11T13:44:21Z">
  <state datetime="2020-10-26">REFERRED</state>
  <status>
    <introduced datetime="2020-10-26"/>
  </status>
  <introduced datetime="2020-10-26"/>
  <titles>
    <title type="display">Accelerating Access to Critical Therapies for ALS Act</title>
    <title type="short" as="introduced">Accelerating Access to Critical Therapies for ALS Act</title>
    <title type="official" as="introduced">A bill to direct the Secretary of Health and Human Services to support research on, and expanded access to, investigational drugs for amyotrophic lateral sclerosis, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="C001088"/>
  <cosponsors>
    <cosponsor bioguide_id="B001236" joined="2020-11-30"/>
    <cosponsor bioguide_id="C001047" joined="2020-12-03"/>
    <cosponsor bioguide_id="C001096" joined="2020-12-16"/>
    <cosponsor bioguide_id="F000062" joined="2020-12-16"/>
    <cosponsor bioguide_id="G000555" joined="2020-12-10"/>
    <cosponsor bioguide_id="H001061" joined="2020-12-21"/>
    <cosponsor bioguide_id="J000300" joined="2020-12-21"/>
    <cosponsor bioguide_id="K000383" joined="2020-12-03"/>
    <cosponsor bioguide_id="L000174" joined="2020-12-21"/>
    <cosponsor bioguide_id="L000594" joined="2020-12-10"/>
    <cosponsor bioguide_id="M001183" joined="2020-12-21"/>
    <cosponsor bioguide_id="M000934" joined="2020-12-30"/>
    <cosponsor bioguide_id="M001153" joined="2020-10-26"/>
    <cosponsor bioguide_id="S001181" joined="2020-11-30"/>
    <cosponsor bioguide_id="S001191" joined="2020-12-30"/>
  </cosponsors>
  <actions>
    <action datetime="2020-10-26">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2020-10-26" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="8662" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Advisory bodies"/>
    <term name="Congressional oversight"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Government information and archives"/>
    <term name="Health care coverage and access"/>
    <term name="Health care quality"/>
    <term name="Health information and medical records"/>
    <term name="Health programs administration and funding"/>
    <term name="Health promotion and preventive care"/>
    <term name="Medical research"/>
    <term name="Medical tests and diagnostic methods"/>
    <term name="Neurological disorders"/>
    <term name="Public contracts and procurement"/>
    <term name="Research administration and funding"/>
    <term name="Research and development"/>
  </subjects>
  <amendments/>
  <summary date="2020-12-28T16:58:52Z" status="Introduced in Senate">Accelerating Access to Critical Therapies for ALS Act

This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions.

The Department of Health and Human Services (HHS) shall award grants to eligible entities to support research on and facilitate access to investigational drugs that diagnose or treat ALS. The Food and Drug Administration shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other severely debilitating neurodegenerative diseases.

HHS shall also establish the Collaborative for Neurodegenerative Diseases, which shall support the development and regulatory approval of drugs that address ALS and other rare neurodegenerative diseases.</summary>
</bill>
